Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 222.16%: Read This Before Placing a Bet

Shares of Monte Rosa Therapeutics (GLUE) have gained 22.5% over the past four weeks to close the last trading session at $5.01, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of$16.14 indicates a potential upside of 222.2%.The mean estimate comprises seven short-term price targets with a standard deviation of $3.98. While the lowest estimate of$10 indicates a 99.6% increase from ...